Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-66

In the last 12 months or so and particularly since the formation of the new BoD, Management team, SAB and the Fight MND funding for the Open ended trial PAA have had the after burners on.
I am very happy with the progress and the direction we are heading, the next 12 months will be pivotal for PAA, very exciting times ahead.

Have been looking back through some announcements/ releases, and came across this

MPL 2 Patent Family covers AADs and is directed at mTOR (mammalian Target of Rampamycin)
neurological diseases, such as Alzheimer’s disease, Huntington’s disease, etc. and chronic
inflammatory diseases, rheumatoid arthritis and transplanted organ rejection; fibrotic diseases of
the liver, heart and lungs. It also extends cancer claims to include solid tumours and leukemias,
lymphomas, etc.
The patent family derives from application WO2014/022879, Compound for the treatment of
mTOR pathway related diseases, filed by Pitney Pharmaceuticals on 5 August 2013. It is pending
in major markets of the world.
From here (page 10)
PHARMAUSTvaluation08-09-15(signed).pdf
Talk about a bottle of Dr Good.

Good luck to all.